Lipocine Inc Market Cap ($12.04 Million)
Market Cap & Net Worth: Lipocine Inc (LPCN)
Lipocine Inc market cap. Lipocine Inc (NASDAQ:LPCN) has a market capitalization of $12.04 Million ($12.04 Million) as of November 4, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #26441 globally and #5532 in its home market, demonstrating a 0.69% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Lipocine Inc's stock price $1.46 by its total outstanding shares 8244253 (8.24 Million). Also see LPCN cash flow metrics for how efficiently the company converts equity into cash flow.
Lipocine Inc Market Cap History (2015–2026)
Lipocine Inc market cap history from 2015 to 2026. Data shows change from $1.81 Billion to $12.04 Million (-36.38% CAGR). Check Lipocine Inc share price for real-time trading data and today's change.
Index Memberships
Lipocine Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.61 Trillion | 0.00% | #737 of 976 |
|
NASDAQ Composite
IXIC
|
$40.20 Trillion | 0.00% | #2414 of 3165 |
Weight: Lipocine Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Lipocine Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Lipocine Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore net asset growth rate of Lipocine Inc to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
33.49x
Lipocine Inc's market cap is 33.49 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2018 | $182.20 Million | $428.03K | -$11.66 Million | 425.67x | N/A |
| 2019 | $53.94 Million | $164.99K | -$13.01 Million | 326.96x | N/A |
| 2020 | $190.61 Million | $0.04 | -$20.96 Million | 4765178234.00x | N/A |
| 2021 | $138.90 Million | $16.14 Million | -$634.40K | 8.61x | N/A |
| 2022 | $55.75 Million | $500.00K | -$10.76 Million | 111.51x | N/A |
| 2023 | $23.00 Million | $-2.85 Million | -$16.35 Million | -8.07x | N/A |
| 2024 | $40.23 Million | $11.20 Million | $8.35K | 3.59x | 4817.04x |
| 2025 | $66.20 Million | $1.98 Million | -$9.63 Million | 33.49x | N/A |
Competitor Companies of LPCN by Market Capitalization
Companies near Lipocine Inc in the global market cap rankings as of November 4, 2026. Also see total assets of Lipocine Inc for a full breakdown of the balance sheet.
Key companies related to Lipocine Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #180 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #368 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #414 globally with a market cap of $68.22 Billion USD ( AU$96.41 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #494 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #180 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $530.76 |
| #368 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $973.36 |
| #414 | CSL Ltd | AU:CSL | $68.22 Billion | AU$198.72 |
| #494 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $228.44 |
Market Capitalization of Lipocine Inc (2015–2026)
Market capitalization of Lipocine Inc from 2015 to today. Between 2015 and today, Lipocine Inc's market cap moved from $1.81 Billion to $ 12.04 Million, with a yearly change of -36.38%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $12.04 Million | -81.82% |
| 2025 | $66.20 Million | +64.55% |
| 2024 | $40.23 Million | +74.91% |
| 2023 | $23.00 Million | -58.74% |
| 2022 | $55.75 Million | -59.86% |
| 2021 | $138.90 Million | -27.12% |
| 2020 | $190.61 Million | +253.34% |
| 2019 | $53.94 Million | -70.39% |
| 2018 | $182.20 Million | -62.21% |
| 2017 | $482.12 Million | -6.52% |
| 2016 | $515.76 Million | -71.54% |
| 2015 | $1.81 Billion | -- |
End of Day Market Cap According to Different Sources
On Nov 4th, 2026 the market cap of Lipocine Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $12.04 Million USD |
| MoneyControl | $12.04 Million USD |
| MarketWatch | $12.04 Million USD |
| marketcap.company | $12.04 Million USD |
| Reuters | $12.04 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Lipocine Inc
Lipocine Inc., a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs using its proprietary delivery technology. The company offers TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate. It also develops LPCN 1154 (BRLIZIO), an oral neuro-steroid in a Phase 3 pivotal trial for postpartum depression; LPCN 1… Read more